Expression levels of PDYN and OPRM1 genes in SH-SY5Y cells exposed to 50 Hz electromagnetic field
More details
Hide details
Department of Biology, College of Sciences, Shiraz University, Shiraz, Iran
Mostafa Saadat   

Department of Biology, College of Sciences, Shiraz University, Shiraz 71467-13565, Iran. Tel: +9871 36137432; Fax: +9871 32280916.
Submission date: 2017-07-04
Acceptance date: 2017-09-18
Online publication date: 2018-05-28
Publication date: 2019-10-31
Pol. Ann. Med. 2019;26(1):36–40
Extremely low-frequency (ELF) (<300 Hz) electromagnetic fields (EMFs) may significantly affect several biological processes at the cellular and molecular level. Considering that ELF-EMF is abundant in our environment and associated with reactive oxygen species (ROS) production, exposure to EMF should be considered as a public health issue. ELF-EMF may alter the mRNA expression levels of several genes. Prodynorphin (PDYN, OMIM: 131340), precursor of several endogenous opioid neuropeptides, and opioid receptor mu-1 (OPRM1, OMIM: 600018) a member of opioid receptor family, are associated with nociception and drug-dependency.

This study was conducted to elucidate the effects of ELF-EMF on expression levels of PDYN and OPRM1.

Material and methods:
Human SH-SY5Y cells were exposed first to EMF and harvested at three time points post exposure; immediately after exposure (0h), 2h and 4h after exposure. The 0.50 mT intensity of 50 Hz EMF and two exposure conditions (‘15 min field-on/15 min field-off’ and ‘30 min field-on continuously’) were used. Using quantitative real-time PCR, the relative PDYN and OPRM1 mRNA expression levels were calculated.

Results and discussion:
After continuous exposure to ELF-EMF, analysis of variance revealed a significant reduction of PDYN mRNA expression levels at 0 hours and 2 hours time points (F = 23.86; df = 3, 8; P < 0.001). The OPRM1 mRNA expression levels did not show any significant alteration between the examined conditions.

In the present study the continuous exposure condition of ELF-EMF was associated with the lower expression levels of the PDYN.

This study was supported by Shiraz University, Iran.
No competing interests are declared by any of the authors.
Schwarzer C. 30 years of dynorphins – new insights on their functions in neuropsychiatric diseases. Pharmacol Therapeut. 2009;123(3):353–370.
Knoll AT, Carlezon WA Jr. Dynorphin, stress, and depression. Brain Res. 2010;1314:56–73.
Wittmann W, Schunk E, Rosskothen I, et al. Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. Neuropsychopharmacology. 2009;34(3):775–785.
Saify K, Saadat M. Expression levels of OPRM1 and PDYN in human SH-SY5Y cells treated with morphine and methadone. Life Sci. 2016;150:39–41.
Zimprich A, Kraus J, Wöltje M, et al. An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J Neurochem. 2000;74(2):472–477.
Saify K, Saadat I, Saadat M. Association between VNTR polymorphism in promoter region of prodynorphin (PDYN) gene and heroin dependence. Psychiatry Res. 2014;219(3):690–692.
Rouault M, Nielsen DA, Ho A, Kreek MJ, Yuferov V. Cell-specific effects of variants of the 68-base pair tandem repeat on prodynorphin gene promoter activity. Addict Biol. 2011;16(2):334–346.
Wei SG, Zhu YS, Lai JH, Xue HX, Chai ZQ, Li SB. Association between heroin dependence and prodynorphin gene polymorphisms. Brain Res Bull. 2011;85(3–4):238–242.
Butelman ER, Yuferov V, Kreek MJ. κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci. 2012;35:587–596.
Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev. 2005;57(1):1–26.
Schwantes-An TH, Zhang J, Chen LS, et al. Association of the OPRM1 variant rs1799971 (A118G) with non-specific liability to substance dependence in a collaborative de novo meta-analysis of European-Ancestry cohorts. Behav Genet. 2016;46(2):151–169.
Hwang IC, Park JY, Myung SK, Ahn HY, Fukuda K, Liao Q. OPRM1 A118G gene variant and postoperative opioid requirement: a systematic review and meta-analysis. Anesthesiology. 2014;121(4):825–834.
Markov MS. Magnetic field therapy: a review. Electromagn Biol Med. 2007;26(1):1–23.
SCENIHR. 2015. Opinion on potential health effects of exposure to electromagnetic fields (EMF). Accessed: April 18, 2018.
Del Seppia C, Ghione S, Luschi P, Ossenkopp KP, Choleris E, Kavaliers M. Pain perception and electromagnetic fields. Neurosci Biobehav Rev. 2007;31(4):619–642.
Calcabrini C, Mancini U, De Bellis R, et al. Effect of extremely low-frequency electromagnetic fields on antioxidant activity in the human keratinocyte cell line NCTC 2544. Biotechnol Appl Biochem. 2017;64(3):415–422.
Park JE, Seo YK, Yoon HH, Kim CW, Park JK, Jeon S. Electromagnetic fields induce neural differentiation of human bone marrow derived mesenchymal stem cells via ROS mediated EGFR activation. Neurochem Int. 2013;62(4):418–424.
Ayşe IG, Zafer A, Sule O, Işil IT, Kalkan T. Differentiation of K562 cells under ELF-EMF applied at different time courses. Electromagn Biol Med. 2010;29(3):122–130.
Hardell L, Sage C. Biological effects from electromagnetic field exposure and public exposure standards. Biomed Pharmacother. 2008;62(2):104–109.
Mahmoudinasab H, Sanie-Jahromi F, Saadat M. Effects of extremely low-frequency electromagnetic field on expression levels of some antioxidant genes in MCF-7 cells. Mol Biol Res Commun. 2016;5(2):77–85.
Manzella N, Bracci M, Ciarapica V, et al. Circadian gene expression and extremely low‐frequency magnetic fields: An in vitro study. Bioelectromagnetics. 2015;36(4):294–301.
Bernal-Mondragón C, Arriaga-Avila V, Martínez-Abundis E, Barrera-Mera B, Mercado-Gómez O, Guevara-Guzmán R. Effects of repeated 9 and 30-day exposure to extremely low-frequency electromagnetic fields on social recognition behavior and estrogen receptors expression in olfactory bulb of Wistar female rats. Neurol Res. 2017;39(2):165–175.
Leone L, Fusco S, Mastrodonato A, et al. Epigenetic modulation of adult hippocampal neurogenesis by extremely low-frequency electromagnetic fields. Mol Neurobiol. 2014;49(3):1472–1486.
Sanie-Jahromi F, Saadat I, Saadat M. Effects of extremely low frequency electromagnetic field and cisplatin on mRNA levels of some DNA repair genes. Life Sci. 2016;166:41–45.
Manzella N, Bracci M, Ciarapica V, et al. Extremely low-frequency electromagnetic fields affect transcript levels of neuronal differentiation-related genes in embryonic neural stem cells. PLoS One. 2014;9(3):e90041.
Ma Q, Chen C, Deng P, et al. Extremely low-frequency electromagnetic fields promote in vitro neuronal differentiation and neurite outgrowth of embryonic neural stem cells via up-regulating TRPC1. PloS one. 2016;11(3):e0150923.
Sanie-Jahromi F, Saadat M. Different profiles of the mRNA levels of DNA repair genes in MCF-7 and SH-SY5Y cells after treatment with combination of cisplatin, 50-Hz electromagnetic field and bleomycin. Biomed Pharmacother. 2017;94:564–568.
Mahmoudinasab H, Saadat M. Short-term Exposure to 50-Hz Electromagnetic Field and Alterations in NQO1 and NQO2 Expression in MCF-7 Cells. Open Access Maced J Med Sci. 2016;4:548–550.
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3(6):1101–1108.
Xu B, Wang Z, Li G, et al. Heroin-administered mice involved in oxidative stress and exogenous antioxidant-alleviated withdrawal syndrome. Basic Clin Pharmacol Toxicol. 2006;99(2):153–161.
Qiusheng Z, Yuntao Z, Rongliang Z, Dean G, Changling L. Effects of verbascoside and luteolin on oxidative damage in brain of heroin treated mice. Pharmazie. 2005;60(7):539–543.
Kovatsi L, Njau S, Nikolaou K, Topouridou K, Papamitsou T, Koliakos G. Evaluation of prooxidant-antioxidant balance in chronic heroin users in a single assay: an identification criterion for antioxidant supplementation. Am J Drug Alcohol Abuse. 2010;36(4):228–232.
Soykut B, Eken A, Erdem O, et al. Oxidative stress enzyme status and frequency of micronuclei in heroin addicts in Turkey. Toxicol Mech Methods. 2013;23(9):684–688.
Saify K, Saadat I, Saadat M. Down-regulation of antioxidant genes in human SH-SY5Y cells after treatment with morphine. Life Sci. 2015;144:26–29.
Anderson SA, Michaelides M, Zarnegar P, et al. Impaired periamygdaloid-cortex prodynorphin is characteristic of opiate addiction and depression. J Clin Invest. 2013;123(12):5334–5341.
Yuferov V, Ji F, Nielsen DA, et al. A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. Neuropsychopharmacology. 2009;34(5):1185–1197.